ARQT · NASDAQ · STOCK
Arcutis Biotherapeutics, Inc.
$26.21
52W $14.08 – $31.77
64/100
$3.28B
118.8
1.53
Is ARQT Bullish or Bearish?
Bullish.
Innellis AI committee rates Arcutis Biotherapeutics, Inc. (ARQT) Buy with a composite score of 64/100
, based on 5 analysts with 60% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.26 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.74 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- ROE of 15.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.58 means this name should amplify a favorable market regime — Macro
- News sentiment is positive (+0.27 across 21 articles, 14d) — News
Bear Case
- P/E of 114.1 is expensive by classic value standards — Value
- Price-to-book of 18.8x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
64/100
Agreement
60%
Analysts
5
Conviction
Contested
Sector Rank
Top 22%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 15.0% shows genuine earnings power backing the valuation
− P/E of 114.1 is expensive by classic value standards
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 76.1% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 21 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
44.7
Neutral
MACD Histogram
-0.294
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$21.13
Resistance
$28.60
Bollinger %B
0.24
Inside Bands
Price vs Moving Averages
EMA 9
$26.40
Below
EMA 21
$26.72
Below
EMA 50
$26.08
Above
EMA 200
$23.94
Above
Fundamental Analysis
Valuation
33
Profitability
33
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
118.8×
P/B Ratio
15.52×
PEG Ratio
0.02
Dividend Yield
0.00%
52W High
$31.77
52W Low
$14.08
Quality & Growth
ROE
-851.9%
ROA
-372.8%
Gross Margin
9114.3%
Operating Margin
738.2%
Revenue Growth YoY
—
Debt / Equity
0.52
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 118.8 (rich relative to a 15-40x range); Price-to-book of 15.5x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -8.5%; Return on assets of -3.7%; Net margin of 6.1%; Gross margin of 91.1%; Current ratio of 2.92 (healthy short-term liquidity); Debt-to-equity of 0.52; Free cash flow per share is positive (0.30); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ARQT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →